First UK Patient Treated with CSL Behring’s Gene Therapy for Haemophilia B - Pharmafile

First UK patient treated with CSL Behring’s gene therapy for Haemophilia B - Pharmafile

CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene dezaparvovec) through the NHS, marking a significant milestone in haemophilia B treatment and NHS access to gene therapies. The treatment was administered at Guy’s and St Thomas’ NHS Foundation Trust in London to a patient from the North East of […] The post First UK patient treated with CSL Behring’s gene therapy for Haemophilia B appeared first on Ph…

Guy’s and St Thomas’ treats first patient in UK with life-changing gene therapy treatment

Guy’s and St Thomas’ treats first patient in UK with life-changing gene therapy treatment m.barker Thu, 19/06/2025 - 12:07 The team involved in the UK first Guy’s and St Thomas’ has become the first Trust in the UK to treat a patient on the NHS with a new, potentially life-changing drug for haemophilia B. Haemophilia B is an inherited bleeding disorder caused by a lack of Factor IX, an important blood-clotting protein. Patients often experience…